Payment overview · 2025
General Payments
$510.04
28 reported records · 6 companies
Healthcare provider profile · identity verified
William Morgan, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, MS · NPI 1316477607
Verified facts
What the public records show
CMS Open Payments records show William Morgan, MD received $510.04 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.72 | 31.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.54 | 31.9% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.48 | 20.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.49 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.65 | 4.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $504.49 | 27 |
| Education | $5.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.99 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $132.19 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.48 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $91.65 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.07 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 106 |
| Losartan Potassium | Losartan Potassium | 359 | 105 |
| Gabapentin | Gabapentin | 355 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 79 |
| Lisinopril | Lisinopril | 304 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 91 |
| Sertraline Hcl | Sertraline Hcl | 256 | 77 |
| Carvedilol | Carvedilol | 255 | 74 |
| Potassium Chloride | Potassium Chloride | 248 | 68 |
| Alprazolam | Alprazolam | 237 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 54 |
| Omeprazole | Omeprazole | 190 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 57 |
| Metformin Hcl Er | Metformin Hcl | 160 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 48 |
| Furosemide | Furosemide | 155 | 50 |
| Metformin Hcl | Metformin Hcl | 154 | 51 |
| Famotidine | Famotidine | 151 | 53 |
| Chlorthalidone | Chlorthalidone | 134 | 45 |
| Eliquis | Apixaban | 126 | 17 |
| Montelukast Sodium | Montelukast Sodium | 126 | 38 |
| Tramadol Hcl | Tramadol Hcl | 122 | 38 |
| Ozempic | Semaglutide | 120 | 21 |
| Ezetimibe | Ezetimibe | 115 | 35 |
| Warfarin Sodium | Warfarin Sodium | 113 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 43 |
| Spironolactone | Spironolactone | 106 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 30 |
| Allopurinol | Allopurinol | 93 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 65 |
| Trazodone Hcl | Trazodone Hcl | 82 | 27 |
| Meloxicam | Meloxicam | 77 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 25 |
| Azithromycin | Azithromycin | 73 | 57 |
| Celecoxib | Celecoxib | 73 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 25 |
| Pregabalin | Pregabalin | 65 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 14 |
| Simvastatin | Simvastatin | 62 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 43 |
| Glimepiride | Glimepiride | 60 | 21 |
| Methylprednisolone | Methylprednisolone | 57 | 51 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 14 |
| Prednisone | Prednisone | 55 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Lovastatin | Lovastatin | 53 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 16 |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 15 |
| Azelastine Hcl | Azelastine Hcl | 47 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 13 |
| Torsemide | Torsemide | 46 | 11 |
| Cephalexin | Cephalexin | 45 | 38 |
| Linzess | Linaclotide | 44 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 17 |
| Ondansetron Odt | Ondansetron | 42 | 31 |
| Benazepril Hcl | Benazepril Hcl | 41 | 13 |
| Atenolol | Atenolol | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Glipizide | Glipizide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 26 |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | 15 |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Cefdinir | Cefdinir | 24 | 21 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 13 |
| Diazepam | Diazepam | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $510.04 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, OFEV, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error